You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

 

Online download statistics by month:

Online download statistics by month: November 2023 to August 2024

AbstractFullPdf
Nov 2023148013
Dec 20233803
Jan 20245102
Feb 20243801
Mar 20242803
Apr 20243203
May 20243800
Jun 20241600
Jul 20242003
Aug 20241602
Total425030